Progress in autoantibodies associated with esophageal squamous cell carcinoma.
- Author:
Kaijuan JI
1
;
Chao SUN
2
;
Yan ZHAO
3
Author Information
1. Medical Research Center, Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou 225000; The Blood Transfusion Department, the First People's Hospital of Guannan County, Lianyungang 222500, China.
2. Department of Cardiothoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou 225000, China.
3. Medical Research Center, Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou 225000, China. *Corresponding author, E-mail: zhaoyan1982@foxmail.com.
- Publication Type:English Abstract
- MeSH:
Humans;
Autoantibodies/immunology*;
Esophageal Neoplasms/therapy*;
Esophageal Squamous Cell Carcinoma/immunology*;
Biomarkers, Tumor/immunology*;
Prognosis;
Carcinoma, Squamous Cell/diagnosis*;
Animals
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(4):363-371
- CountryChina
- Language:Chinese
-
Abstract:
The early diagnosis and precise treatment of esophageal squamous cell carcinoma (ESCC) hold significant clinical value in improving patient survival rate. Current diagnostic methods for early-stage ESCC primarily rely on invasive procedures and endoscopy, which can cause discomfort and financial burden for patients. Therefore, non-invasive biomarkers with high sensitivity and specificity present a more suitable alternative for early tumor diagnosis. Tumor associated autoantibodies (TAAb), identified as potential biomarkers, have considerable clinical implications for the early diagnosis, treatment monitoring, and prognosis assessment of ESCC. Here in we aim to summarize recent research on ESCC-related autoantibodies, including their background, types and development, analyze the potential of those autoantibodies in clinical diagnosis, treatment monitoring, and prognosis assessment, and also discuss the limitations of existing research and future directions. The goal is to provide a theoretical foundation for the early diagnosis and personalized treatment of ESCC.
